恒瑞医药：SHR-4610注射液获临床试验批准

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Summary by Categories - Clinical Trial Approval - The National Medical Products Administration has issued a clinical trial approval notice for SHR-4610 injection [1] - The clinical trials are set to commence in the near future [1] - Product Development - SHR-4610 injection is an innovative anti-tumor drug independently developed by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - Research and Development Investment - The cumulative R&D investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1]